Drugs / LCL161
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03111992 | Dec 2017 → Mar 2020 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02890069 | Oct 2016 → Feb 2022 | colorectal cancer, non-small cell lung carcinoma, renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02649673 | Mar 2016 → Jul 2021 | ovarian carcinoma, small cell lung carcinoma | SCRI Development Innovations, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01934634 | Mar 2014 → Mar 2016 | pancreatic ductal adenocarcinoma | US Oncology Research | Unknown | No outcome recorded |
| Phase 1 | NCT01968915 | Nov 2013 → Jun 2015 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01240655 | Apr 2011 → Jan 2015 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01098838 | Nov 2008 → Jan 2011 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02098161 | Dec 2014 → May 2022 | myelofibrosis, primary myelofibrosis | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01617668 | Aug 2012 → Sep 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCL161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02890069 ↗ |
| Known as | Nvp-lcl 161 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2431768 ↗ |
| Action | Inhibit | “LCL161 antagonizes the function of inhibitor of apoptosis proteins (IAPs), thereby promoting cancer cell death.” PMID 25113756 ↗ Aug 2014 |
| Modality | Small molecule | “small molecular weight Smac-mimetic compound” NCT01934634 ↗ |
| Route | Oral | “LCL161 was administered orally, once weekly, on a 21-day cycle to adult patients with advanced solid tumors” PMID 25113756 ↗ Aug 2014 |